Skinvisible Inc (QB) (SKVI) Share Price

I agree.

Whenever I get unsolicited emails, I suspect a Pump and Dump is being put into motion. We shall see.

Not sure what you are asking - can you refresh it please?

Being set up?

Being set up?

You need volume and a stock price rise for a Pump and dump.

Maybe a P&D in the making.......

Pump and dump?

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV – January 23rd, 2025 – Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), an innovative topical pharmaceutical research and development company,

today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment.



Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome. Netherton Syndrome is a hereditary disorder affecting the skin, hair, and immune system, currently lacking an approved treatment or cure. Quoin is responsible for obtaining all FDA and other regulatory body approvals necessary to market the products in the US and other countries. Upon the successful completion of FDA or EU approval, Skinvisible is entitled to receive a milestone payment of $5 million and ongoing royalties from sales.



LICENSEE CLINICAL AND REGULATORY SUCCESS:



Skinvisible’s licensee, Quoin Pharmaceuticals, Inc. (NASDAQ: QNRX) reported multiple positive developments for QRX003, which utilizes Skinvisible's Invisicare technology and its formulation for the rare skin disease: Netherton Syndrome:



Key Recent Developments:

FDA clearance for Netherton Syndrome "whole body" study at Northwestern University

Significant clinical improvements in both open label and pediatric studies including subject’s disease classification improved from “severe” to “mild” after 6 weeks dosing

No adverse events or safety concerns reported to date from each of Quoin’s ongoing clinical studies in Netherton Syndrome subjects

International expansion of studies to UK, Ireland, and Saudi Arabia

Netherton Syndrome product QRX003 with Invisicare delivery technology licensed in 60 countries



"We anticipate a significant milestone with our licensee potentially receiving the first FDA approval for a formulation using our Invisicare delivery technology," said Terry Howlett, President and CEO of Skinvisible. "This validates our strategy of developing innovative topical and transdermal therapeutics for other indications. As our licensee advances their clinical trials, we remain committed to supporting their efforts to bring this groundbreaking treatment to Netherton Syndrome patients worldwide."

Along with its ongoing research and development, Skinvisible continues to actively seek strategic partnerships with pharmaceutical and biotech companies to bring topical and transdermal Invisicare formulations to the market including the first transdermal obesity therapies and explore broader applications of its delivery platform with other small molecules.



For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please contact info@skinvisible.com.



About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.



Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby including with respect to the possible development of any such products, the acceptance of any such products in the market place, the size of any such markets, the ability of any product candidates to be approved by the U.S. Food and Drug Administration among others. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending September 30, 2024).

typical

Where did everybody go?

anybody buying after today's news?

When it drops back down to .02 after the R/S,then buy.

SKVI: effective Jan. 4,2019 a one for 50 reverse split:

http://otce.finra.org/DLSymbolNameChanges

SKVI Offers Long-term Protection Against Highly Contagious Viruses

Skinvisible’s (OTCQB: SKVI) antiseptic hand sanitizer lotion, DermSafe®, incorporates the company’s proprietary Invisicare® drug delivery technology and is 99.9 percent effective against a list of deadly bacteria and viruses. An article discussing the company reads: “One application of DermSafe provides a four-hour protective barrier that binds to the skin and actively combats the spread of germs between people and hard surfaces. The active ingredient is four percent chlorhexidine gluconate (CHG), the same active ingredient found in soaps used in hospital operating rooms. DermSafe offers long-term protection and destroys both gram-negative and gram-positive bacteria and viruses (http://nnw.fm/8dJbP). It has been tested and proven effective against a host of infectious germs, including Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli) and salmonella. Sales of DermSafe have already taken off in China, and the product will be marketed throughout the country.”

To view the full article, visit http://nnw.fm/ZGnU5

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com

SKVI's Potential Merger Set to Deliver an Alternative as Opioid Crisis Deepens

- Developing opioid alternative for pain treatment
- Well-positioned to capture market share as an opioid substitute
- Timely market entry as opioid abuse reduces U.S. life expectancy

Opioids are taking a toll on the nation. Data released by the Centers for Disease Control and Prevention (CDC) show that, for the second year in a row, life expectancy in the United States declined due to deaths from opioid overdoses. A major contributing factor to these alarming statistics has been the increasing appearance of synthetic opioid fentanyl. The drug is immensely powerful and is suspected to be the reason why many overdoses turn out to be fatal. Compounding the crisis is the double-headed problem that fentanyl, although manufactured and marketed legally, is also produced and distributed illegally. This duality offers a pernicious path to illicit use for patients introduced to prescription opioids for pain relief. Luckily, alternatives to pain management are under development. One such option will emanate from the proposed merger between Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. The combined entity’s proposed first product candidate, QRX001, is expected to be developed for the treatment of post-surgical pain.

The rising use of destructive opioids is reversing the gains eked out by advances in medical science. Since 1963, U.S. life expectancy has improved, as newer drugs and better procedures are keeping us alive for longer. However, owing to increasing reliance on opioids, that trend was reversed in 2015 and 2016. Drug overdoses have now surpassed heart disease as the leading cause of death for Americans under the age of 55, according to the New York Times (http://nnw.fm/BZPr1), and fentanyl appears to be the chief malefactor.

Developed in Belgium in the late 1950s, fentanyl is a mighty medication with an analgesic potency that’s 80 times as high as that of morphine. It was introduced into medical practice as an anesthetic in the 1960s because of its effectiveness and, in different forms, remains in extensive use today. By the mid-1970s, illicit fentanyl had begun to appear alongside heroin and cocaine as the fare of drug traffickers. It is now eclipsing those narcotics as a source of concern because of its murderous track record. While the biological effects of fentanyl are indistinguishable from those of heroin, for example, newly developed illicit analogues may be hundreds of times as potent. As a result, the possibility of overdose for a fentanyl user is significantly increased. Moreover, the crisis may get worse. Fentanyl is now commonly being added to boost the effects of heroin and cocaine, and it may even be passed off as those substances.

These disturbing developments make the need for gentler alternatives to opioids more pressing. Despite the ravage they cause, their use continues to increase. Consequently, the U.S. opioid market, currently estimated at around $12 billion, is expected to continue growing at a CAGR of 4.6 percent until 2024 (http://nnw.fm/4zmCF).

Replacing just a fraction of that use with an option like QRX001 is likely to lift the dark cloud hanging over the nation by weakening the forces driving the opioid onslaught. QRX001, to be the lead drug candidate of the post-merger entity (Quoin Pharmaceuticals Inc.), is a single-use transdermal non-competitive NMDA receptor antagonist intended for the treatment of post-surgical pain. An N-Methyl-D-Aspartate (NMDA) receptor allows the transfer of electrical signals between the brain and the rest of the nervous system. An NMDA receptor antagonist is a drug that inhibits the ability of that NMDA receptor to accept signals, which is very useful when those signals are experienced as pain.

The highly differentiated nature of QRX001 could position it to capture a significant market share either as monotherapy or as a key component of effective multi-modal therapy. As a result, Quoin intends to apply for fast track status for QRX001.

The completion of the merger between Skinvisible and Quoin is subject to the negotiation of a definitive agreement and other customary closing conditions, including Quoin completing a financing round for clinical development.

For more information, visit the company’s website at www.Skinvisible.com

SKVI's Topical Delivery Tech Provides Effective Protection against Deadly Flu Viruses

- Skinvisible’s DermSafe® hand sanitizer provides long-term protection against viruses
- Patented technology delivers active ingredients topically
- Company generates revenue from four income streams

An outbreak of the deadly influenza A (H3N2) virus has devastated families across the United States this winter. Traditionally, the elderly and the very young are most vulnerable to the flu, but, this time around, it is attacking people of all ages. This outbreak follows on the heels of the potent H7N9 avian influenza virus, which has the potential to spread globally, although largely confined to China at present. Hand hygiene is vital to reduce the risk of contracting these flu strains. Skinvisible, Inc. (OTCQB: SKVI) has developed a unique hand sanitizer, DermSafe®, which offers long-term protection against harmful microbes.

DermSafe® uses patented polymer delivery technology developed by Skinvisible called Invisicare®. This proprietary technology binds active ingredients to the skin to enhance their delivery and resists wash-off and rub-off for up to four hours, even with hand washing. It creates a barrier to prevent attack by viruses and damage from toxins, retaining moisture in the skin while allowing normal respiration and perspiration. Left on the skin to do their job, Invisicare® formulations eventually wear off as part of the skin’s natural exfoliation process.

All of Skinvisible’s products utilizing Invisicare® technology are non-drying, as the formulations do not contain any organic solvents such as alcohol, silicones or waxes. Enhanced delivery means a lower dosage of active ingredients is required while still offering improved efficacy, reduced skin irritation and longer duration of action. To validate its marketing claims, the company uses FDA-registered independent laboratories to verify the efficiency of its products.

Through wholly-owned subsidiary Kintari, Skinvisible has developed a range of anti-aging products, including day cream, night cream, sunscreen and hand and body lotion. All of these products use the patented Invisicare® topical delivery technology. The company has 14 global patents for over 40 skincare products powered by Invisicare®. The Kintari website (www.Kintari.com) is a marketing portal for its products, offering consumers the ability to purchase these patented products online.

Looking ahead, Skinvisible’s development pipeline using Invisicare’s topical delivery technology includes products for acne, dermatitis, skin cancer, warts and first-aid pain relief, as well as formulations with anti-aging, anti-fungal and anti-inflammatory properties. In November 2017, the company issued a letter of intent to merge with Quoin Pharmaceuticals Limited, a developer of post-surgical pain relief products that replace or reduce opioid use. Quoin is also developing a transdermal formulation for anti-depression treatment of military veterans showing suicidal tendencies related to post-traumatic stress disorder (PTSD).

Skinvisible’s business model provides four revenue streams. By licensing its formulations, the company generates research and development fees for new products. It also charges license fees to secure exclusive territorial rights to a product, while generating ongoing royalties based on a licensee’s sales. Direct revenue is generated from the sale of Kintari products and the sale of the company’s Invisicare® polymers to its clients.

For more information, visit the company’s website at www.Skinvisible.com

SKVI Preparing to Enter the Post-Surgical Pain Management Market through Proposed Merger

Research and development company Skinvisible (OTCQB: SKVI) previously announced the signing of a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited, which would successfully mark the company’s entrance into the post-surgical pain management market. The partnership has the potential to address significant unmet medical needs on the pain management market. An article discussing the company’s endeavor reads: “Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even further. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.”

To view the full article, visit http://nnw.fm/8VkSb

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com

SKVI Aims to Increase Shareholder Value through Proposed Deal with Quoin

- Drug delivery platform ideal for M&A-driven growth
- $80 billion global dermatology market
- $30 billion global over-the-counter skincare market
- Half of the 100 million surgeries performed in the U.S. require post-surgical pain medication, according to Transparency Market Research report

If history repeats itself, as we are often told, then Skinvisible, Inc.’s (OTCQB: SKVI) proposed deal with Quoin Pharmaceuticals Limited (“Quoin”) could increase shareholder value after execution. In late 2017, the company announced its plan to merge with Quoin, a marriage made in heaven that combines Skinvisible’s virtues as a drug delivery developer with Quoin’s position as a producer of post-surgical pain products that replace or diminish opioid use (http://nnw.fm/2pC2r). Over the past two decades, mergers in the pharmaceutical industry have generally resulted in positive returns to shareholders, and today’s market leaders are the ones that have been most active in mergers and acquisitions.

There are many reasons why a merger may make sense. Taking over a rival, for example, means acquiring that rival’s market share and most, if not all, of its revenues. If product lines or business divisions overlap, costs can be cut and synergies exploited. In addition, purchasing a rival or merging with one may mean the acquisition of exciting new products at a much-reduced cost. It may cost the acquirer less to buy the target (and its product line) than to attempt to develop similar products in-house. Also, borrowing costs matter. If interest rates are low and likely to rise, now might be the time to borrow and spend. These are all good rationales for corporate consolidations. However, ‘growth is the main driver for most M&A deals: not just growth in drug distribution scale or earnings growth through cost cutting, but in revenues—and especially share price’, according to McKinsey & Company (http://nnw.fm/F7gdT).

Skinvisible is ideally poised to grow by acquisition, since its core business revolves around a drug delivery methodology that’s applicable to a wide range of topical products. Such ‘platform companies’ have a bright future, since they are enablers rather than competitors to other drug companies. Hedge fund manager Bill Ackman, the founder of Pershing Square Capital Management, opined, ‘“platform companies”—those that grow through bolt-on acquisitions—enrich their shareholders with each new deal…’ (http://nnw.fm/iqK1V). If that is to be believed, there’s little doubt that Skinvisible is treading the right path.

Since 1999, pharmaceutical and cosmeceutical companies have been adopting Skinvisible’s Invisicare® technology, developed through wholly-owned subsidiary Skinvisible Pharmaceuticals, Inc. The technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell its own patented product and combat generic competitors.

Products utilizing Invisicare have been effective at bonding active ingredients to the skin for up to four hours and longer. Invisicare is non-occlusive; it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. This allows enhanced delivery performance for a variety of topicals resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agents required. The ‘invisible’ polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

With a $80 billion global dermatology market and a $30 billion global over-the-counter skincare market, the patented polymer delivery system for topical products developed by Skinvisible has a great deal of potential to add shareholder value.

For more information, visit the company’s website at www.Skinvisible.com

SKVI DermSafe Hand Sanitizer Stops Influenza A from Spreading

Skinvisible (OTCQB: SKVI), a developer of innovative drug delivery technology, through its Kintari subsidiary, produces the hand sanitizer, DermSafe®. The DermSafe® hand sanitizer stops the spread of the influenza A (H3N2) virus by hand contact. An article discussing the company reads: “DermSafe employs Skinvisible’s patented polymer delivery system, Invisicare®, which improves the delivery of topically applied skin care products, thereby enhancing the efficacy of the active ingredients. The unique process extends the time that the product remains active on the skin and is specifically formulated to transport active ingredients that are insoluble in water without using alcohol, silicones, waxes or other organic solvents.”

To view the full article, visit http://nnw.fm/w4FsM

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com

SKVI Products Can Offer Protection against Highly Contagious Viruses like H3N2

- 2018 flu season could cost U.S. businesses $15 billion in lost productivity
- Winter Olympics hit with norovirus, sickening 128 Olympic workers
- Centers for Disease Control and Prevention urging public to wash hands, use hand sanitizer in battle against infection
- DermSafe® antimicrobial hand sanitizer is 99.9 percent effective against a list of deadly bacteria and viruses

It’s a simple phrase: “Wash your hands and use a hand sanitizer,” but doing it correctly and with the right product can make the difference when it comes to protection against a nasty bacteria or virus. Using an antiseptic hand sanitizer lotion such as DermSafe®, which incorporates Skinvisible’s (OTCQB: SKVI) proprietary Invisicare® drug delivery technology, is another vital tool offering a barrier against potentially serious illnesses. Skinvisible Pharmaceuticals, Inc., developer of over 40 topical prescription, over-the-counter and cosmeceutical products using its patented Invisicare® polymer delivery systems, donated over 1,000 bottles of DermSafe® to the Canadian Olympic team for the 2016 Summer Games in Rio (http://nnw.fm/TRA1x), the company has now sent the same supply for the Olympic team in South Korea for the 2018 Winter Games. It’s a timely donation and one that could make a significant difference to the welfare of the team.

In fact, every athlete at the 2018 Winter Olympic Games in Pyeongchang, South Korea, is taking extra precautions to stay healthy, especially after an outbreak of the highly contagious norovirus sickened more than 120 security staff and others, prompting organizers to deploy 900 military personnel to assist at the games (http://nnw.fm/KTPn4). Even more alarming is the continuing number of deaths resulting from an aggressive influenza strain – H3N2 – affecting children and adults living in the continental United States (http://nnw.fm/QQ3gb). The common thread running throughout all of these stories is an admonition from health care professionals urging the public to religiously “wash your hands” and use hand sanitizers. Germs can live on any surface, so washing hands and wearing an antimicrobial hand lotion like DermSafe® is one of the best ways to stop germs from hitching a ride (http://nnw.fm/8uDOL).

One application of DermSafe provides a four-hour protective barrier that binds to the skin and actively combats the spread of germs between people and hard surfaces. The active ingredient is four percent chlorhexidine gluconate (CHG), the same active ingredient found in soaps used in hospital operating rooms. DermSafe offers long-term protection and destroys both gram-negative and gram-positive bacteria and viruses (http://nnw.fm/8dJbP). It has been tested and proven effective against a host of infectious germs, including Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli) and salmonella. Sales of DermSafe have already taken off in China, and the product will be marketed throughout the country.

This year’s flu outbreak could conceivably cost U.S. businesses anywhere from $15 billion to $21 billion in lost productivity, Andrew Challenger, vice president of global employment consulting firm Challenger, Gray & Christmas, Inc., said in a 2017-2018 Flu Season report (http://nnw.fm/Xfq3A). The agency raised itd earlier estimates by 64 percent, stating the 2018 flu virus could cause more than 18 million U.S. employees to miss at least four 8-hour shifts.

“Sick workers may think they are doing the right thing by ‘toughing it out’ and coming into work when they feel ill,” Challenger said in a news article (http://nnw.fm/T9doJ). However, “they are only likely to spread their illness, potentially further interrupting optimum business operations.”

Prevention and protection is the key when it comes to avoiding infectious germs. Although this season’s flu strain is particularly vicious, experts continue to remind the public that washing hands often and applying a long-term, antimicrobial hand sanitizer such as Skinvisible’s DermSafe® offers scientifically-proven protection against bacteria and viruses.

For more information, visit the company’s website at www.Skinvisible.com

SKVI Takes Aim at PTSD-related Suicides through Quoin Partnership

Skinvisible, Inc. (OTCQB: SKVI) is working toward developing a transdermal treatment for post-traumatic stress disorder through its patented Invisicare® technology that could address the devastating number of veteran suicides that occur throughout the country. The company’s proposed merger with Quoin Pharmaceuticals would direct Skinvisible’s drug delivery capacity to boost the bioavailability of Quoin’s promising pharmaceuticals. An article discussing this reads: “Skinvisible, through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology. … Quoin’s two lead products are targeting crises that result in the death of almost 120 people in the U.S. every day. Data released September 15, 2017, by the U.S. Department of Veteran Affairs (“VA”) show that the risk for suicide was 22 percent higher among veterans when compared to civilians.”

To view the full article, visit http://nnw.fm/RlvP5

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com

SKVI, Quoin Pharmaceuticals Proposed Merger to Address Opioid Pain Management Market

- A merger between Skinvisible and Quoin will enable a successful entry on the post-surgical pain management market
- Opioids – which typically refer to oxycodone, hydrocodone, and fentanyl – are highly addictive painkillers; nearly three in 10 Americans prescribed opioids for chronic pain will abuse them
- Opioids are becoming increasingly deadly to Americans; in 2016, two-thirds of drug-related deaths involved opioids; in fact, since 1999, opioid-related deaths in the United States have increased nearly fourfold
- Drug abuse is a burden shared by every state; nearly 63,600 Americans lost their lives to drug overdoses in 2016 – a 21 percent increase over the previous year; from 2000 to 2016, the U.S. Centers for Disease Control and Prevention estimates that more than 600,000 people died from drug overdoses in the United States
- Every 25 minutes, a baby in the United States is born suffering from opioid withdrawal

Skinvisible, Inc. (OTCQB: SKVI) previously announced the signing of a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market. If both parties agree on the terms, the merger should be completed this year, and the resulting entity will operate under the name Quoin Pharmaceuticals Inc. and will continue to trade on the OTCQB market.

Quoin’s strength is within the area of pharmaceutical product development for products that address some of the most serious present-day health problems. Skinvisible is the developer of innovative delivery system technologies that can enhance product delivery and performance.

Quoin’s lead product is QRX001 – a transdermal NMDA receptor antagonist for the effective treatment of pain following surgery. QRX001 delivers up to 72 hours of effective pain relief after surgical interventions. Almost 30 clinical studies have been performed to date on the NMDA receptor antagonist, clearly showing that sub-anesthetic doses reduced 24-hour PCA morphine consumption; reduced post-operative nausea and vomiting; reduced pain intensity; resulted in adverse events that were mild or absent; and generated better results than any other single product or combination. The aim of the product is to also reduce the use of opioids for pain management following an operation.

Upon the product’s launch, QRX001 is expected to provide surgeons with a new and effective alternative to opioids. Opioid abuse has reached an epidemic level in the U.S., with opioid overdoses causing more than 90 deaths per day (http://nnw.fm/V60zK). This number has grown exponentially in the past decade, according to the Centers for Disease Control and Prevention, with opioid use remaining widespread despite the risks. Today, approximately 12 million Americans report that they use pain killers in a non-medicinal way.

The opioid market in the U.S. is estimated at $6 billion annually. With the opioid epidemic now deemed a National Health Emergency, there is a significant push to find new products that reduce or eliminate their use, particularly in a post-surgical setting, which is where 50 percent of people who become addicted first become exposed to these drugs.

In addition to wrecking lives, opioid abuse poses a massive burden on the economy. Adding up money lost from costs related to health care, addiction treatment, reduced work productivity and crime, the Centers for Disease Control and Prevention estimates that the economic burden of the opioid crisis is more than $78.5 billion per year.

Almost half of the victims were first introduced to opioids after undergoing surgery. According to the National Center for Health Statistics, 100 million surgeries take place in the U.S. every year (http://nnw.fm/8fdOl). At least 50 million of these surgical interventions necessitate the use of post-operative pain management pharmaceuticals.

Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even further. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.

The Skinvisible announcement states that new technologies and product synergies between the two companies could potentially provide significant value to shareholders after the merger. Together, Skinvisible and Quoin could maximize their product development opportunities, as noted by Skinvisible President Terry Howlett. The official news release also included a disclaimer regarding ‘forward looking’ statements.

For more information, visit the company’s website at www.Skinvisible.com

wow,,, i think i bought a scam company.....

SKVI's DermSafe Offers Long-term Protection Against H3N2 Flu Virus

Skinvisible’s (OTCQB: SKVI) innovative DermSafe product incorporates the company’s proprietary Invisicare® drug delivery technology and has proven effective against a variety of infectious germs. An article discussing the topical and transdermal product development company reads: “The main curse this season is the particularly malevolent influenza virus H3N2. It is the most dominant strain not only in the U.S. but in Canada and the UK. The virus, experts believe, is mainly transmitted through the air by droplets formed when infected persons cough, sneeze or talk. These droplets land on hard surfaces like door knobs and as soon as one touches it they have just transferred the virus to their hands. With over 90 percent of all germs coming into one’s body from their hands, it is very important to wash them regularly. Regular use of an alcohol hand sanitizer will work as a replacement to hand washing, but it, too, is only immediate and offers no long term protection. Independent studies verify that DermSafe, when applied to the hands, offers a continuous long term kill on bacteria and viruses tested including the H3N2 virus. Consequently, a hand sanitizer like DermSafe is a vital safeguard against the spread of such germs.”

To view the full article, visit http://nnw.fm/8ktVV

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com.

DermSafe from SKVI Kills Killer Flu Virus H3N2 For Up to Four Hours

- DermSafe® hand sanitizer stops spread of virus by hand contact
- Now available in Canada and China
- Employs patented drug delivery technology

As deaths across the nation rise, families of victims struck down by the influenza A (H3N2) virus are beginning to sound the alarm (http://nnw.fm/A3aqr). Warning calls by the relatives of Emily Muth (5), Dylan Winnik (12), Alyssa Alcaraz (12) and Alani Murrieta (20), all of whom succumbed to the deadly strain, relate how murderous this year’s outbreak has been so far. Further proof is furnished by the latest report (http://nnw.fm/T78Go) from the Centers for Disease Control and Prevention (CDC), which indicates that ‘all U.S. states but Hawaii continue to report widespread flu activity and the number of states experiencing “high” influenza activity increased from 26 plus New York City to 32 states plus New York City and Puerto Rico.’ The CDC report also highlights the vulnerability of the young. The number of flu-related pediatric deaths this year has climbed to 30 so far. The crisis has prompted the director of the CDC, Brenda Fitzgerald, to remind the public that washing hands frequently can stop transmission of the virus (http://nnw.fm/8QflB). A hand rub can work just as well if soap and water are not available, according to Fitzgerald. This is all good advice, says Skinvisible, Inc. (OTCQB: SKVI), which, through its Kintari subsidiary, produces the hand sanitizer, DermSafe®. The antiseptic lotion has already joined the fight against the spread of pathogens. It was used by Team Canada at the 2016 Summer Olympics in Brazil, and this year, Skinvisible has donated over 1,000 bottles of DermSafe to the Canadian team for the Winter Olympics in South Korea.

DermSafe non-alcohol hand lotion’s active ingredient is 4% chlorhexidine gluconate (CHG), which offers long-term protection. It destroys both gram-negative and gram-positive bacteria, as well as most viruses, including all of the influenza viruses tested, by providing a long-lasting protective barrier that binds to the skin and actively combats the spread of germs between people and hard surfaces. DermSafe has proven effective against a host of infectious germs including Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli).

DermSafe employs Skinvisible’s patented polymer delivery system, Invisicare®, which improves the delivery of topically applied skin care products, thereby enhancing the efficacy of the active ingredients. The unique process extends the time that the product remains active on the skin and is specifically formulated to transport active ingredients that are insoluble in water without using alcohol, silicones, waxes or other organic solvents.

Invisicare allows products that incorporate its processes to bond more effectively to the skin, thus keeping active ingredients on the skin for up to four hours or longer. Since Invisicare is non-occlusive, it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. This allows enhanced delivery performance for a variety of topicals that results in improved efficacy, longer duration of action, reduced irritation and lower required dosage of active agent. Adding icing to the cake, the ‘invisible’ polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

In June 2017, the company announced that it had completed its first international sale of DermSafe hand sanitizer in China through its agent, InterSpace Global, Inc. (http://nnw.fm/5P9nX). The agreement with InterSpace Global facilitates the export of Skinvisible’s OTC products to mainland China, Hong Kong, Macau, Taiwan, Singapore, Malaysia, Thailand and Korea.

For more information, visit the company’s website at www.Skinvisible.com

SKVI to Enter Pain Management Therapeutics Market through Proposed Merger

Skinvisible (OTCQB: SKVI), a developer of innovative drug delivery technology, recently entered a Letter of Intent (“LOI”) regarding a proposed merger with Quoin Pharmaceuticals. The projected merger would mark the company’s entrance into the pain management therapeutics market. An article discussing the topical and transdermal product development company reads: “Skinvisible has a long, successful history developing and licensing Invisicare®, its patented polymer technology. Enhancing how drugs are delivered on, in, or through the skin, Invisicare® has proven efficacy in a wide range of dermatology and health care products, including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis. Broad applications extend to sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations and, now, with a Quoin merger, the enhanced delivery of important non-opioid pain management medications.”

To view the full article, visit http://nnw.fm/N5LnD

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com.

Proposed Transdermal Treatment for Veterans with PTSD a Top Priority of SKVI and Quoin Pharmaceuticals

- Proposed transdermal product will help veterans struggling with PTSD and suicidal thoughts
- Majority of suicides among military veterans are among those 50 and older
- Suicide rate for U.S. women veterans was 2.5 times higher than civilian adult women
- Presidential executive order signed January 9, 2018, focuses on providing mental health care to former service members

Topical and transdermal product development company Skinvisible, Inc. (OTCQB: SKVI) and its patented Invisicare® technology could provide significant relief to veterans with post-traumatic stress disorder through a proposed transdermal treatment the company expects to develop as it merges with Quoin Pharmaceuticals Ltd. The proposed merger, announced in November 2017 (http://nnw.fm/W1Dp7), will create a robust product portfolio addressing major unmet medical needs, including the devastating number of veteran suicides that occur daily. The company anticipates that the merger will take place in early 2018.

Skinvisible, through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology (http://nnw.fm/7TdgD). The proposed merger with Quoin Pharmaceuticals would combine Skinvisible’s patented and proven novel drug delivery technologies that enhance the delivery of various active ingredients with Quion’s strong pharmaceutical background in post-surgical pain and promising approach to PTSD treatment.

Quoin’s two lead products are targeting crises that result in the death of almost 120 people in the U.S. every day. Data released September 15, 2017, by the U.S. Department of Veteran Affairs (“VA”) show that the risk for suicide was 22 percent higher among veterans when compared to civilians. Among the 20 suicides per day reported to the VA in 2016, 14 of those veterans were not under VA care, VA Secretary Dr. David J. Shulkin stated in presenting the report (http://nnw.fm/SUpm5).

“These findings are deeply concerning, which is why I made suicide prevention my top clinical priority,” Shulkin continued. “This is a national public health issue that requires a concerted, national approach.”

Quoin’s proposed product, QRX002, will be a once-daily transdermal NMDA receptor antagonist for the treatment of suicidal ideation in military veterans with PTSD. About eight million adults are living with PTSD, with anywhere from 11 percent to 20 percent of military veterans experiencing the disorder (http://nnw.fm/n8neT). Currently, the only approved medical treatments for PTSD are standard anti-depressants, which are either ineffective or act very slowly, resulting in a clear unmet medical need to address this growing crisis. Quoin believes that QRX002 may be a candidate for both orphan drug status and breakthrough therapy designation.

“Skinvisible has done an impressive job developing their technology and building a very robust patent portfolio,” Dr. Michael Myers, chairman and CEO of Quoin Pharmaceuticals, stated in a news release. “The utilization of their unique drug delivery technology could, we believe, enable us to achieve the performance targets of our proposed lead products whilst providing for strong patent protection.”

Highlighting the terrible cost that PTSD delivers to the nation’s veterans and their families, President Donald Trump signed an executive order on January 9, 2018, aimed at reducing veteran suicides (http://nnw.fm/NC4tD). The mandate, ‘Supporting Our Veterans During Their Transition from Uniformed Service to Civilian Life’, offers more former service members access to mental health care and focuses on those who are soon-to-leave military service, since they have the highest risk for suicide.

For more information, visit the company’s website at www.Skinvisible.com

down another 16%......

this thing just keeps dropping....

SKVI Set to Repeat Olympic Performance in 2018 with DermSafe

- Targeting $80 billion global skincare and dermatology market
- Revenues to be derived from royalties and other licensing fees
- DermSafe sales have taken off in Greater China
- Pending merger will expand product offerings

Among the winners at the 2016 Summer Olympics in Rio was DermSafe® from Skinvisible’s (OTCQB: SKVI) subsidiary, Kintari. Donated to Team Canada, the non-alcohol hand sanitizing lotion offered protection from pathogens to athletes during the Olympic Games. Now, with the Winter Olympics to be held in South Korea from February 8-25, the need is more pressing. Reported outbreaks of the flu have increased dramatically this year, according to the Centers for Disease Control and Prevention (http://nnw.fm/OKg3z). For the first time since it began monitoring flu patterns, the CDC has reported widespread flu activity in every part of the continental U.S. There is no doubt that antiseptics like DermSafe, which inhibit the spread of contact infections, will take center stage again. There’s a lot at stake. Influenza kills at least 12,000 Americans every year.

The main curse this season is the particularly malevolent influenza virus H3N2. It is the most dominant strain not only in the U.S. but in Canada and the UK. The virus, experts believe, is mainly transmitted through the air by droplets formed when infected persons cough, sneeze or talk. These droplets land on hard surfaces like door knobs and as soon as one touches it they have just transferred the virus to their hands. With over 90 percent of all germs coming into one’s body from their hands, it is very important to wash them regularly. Regular use of an alcohol hand sanitizer will work as a replacement to hand washing, but it, too, is only immediate and offers no long term protection. Independent studies verify that DermSafe, when applied to the hands, offers a continuous long term kill on bacteria and viruses tested including the H3N2 virus. Consequently, a hand sanitizer like DermSafe is a vital safeguard against the spread of such germs.

DermSafe incorporates Skinvisible’s proprietary Invisicare® drug delivery technology, which is effective at bonding active ingredients to the skin for up to four hours and longer. Invisicare is non-occlusive; it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. This allows enhanced delivery performance for a variety of topicals resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

Having made its debut in Rio, DermSafe is set for a repeat performance at the 2018 Winter Olympics in South Korea. Skinvisible has donated over 1,000 bottles of DermSafe to the Canadian Olympic team. DermSafe provides a long-lasting protective barrier that binds to the skin and actively combats the spread of germs between people and between people and hard surfaces. Composed of four percent chlorhexidine gluconate (CHG), the same active ingredient found in soaps used in hospital operating rooms, DermSafe offers long-term protection and destroys both gram-negative and gram-positive bacteria and viruses. It has proven effective against a host of infectious germs, including Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli). Sales of DermSafe have already taken off in China, and the product will be marketed throughout Hong Kong, Macau, Taiwan, Singapore, Malaysia and Thailand.

China, with a population of over 1.6 billion people, exhibits a strong demand for American-made products, driven both by the growth of the middle class in large cities and an increased desire for high quality products. Last year, China imported $2.7 billion in personal care products, and around 69 percent of Chinese women, in one recent survey, said they are in the market for such products and would buy them from online stores, spending an average of $1,800 a year. As well as DermSafe, Kintari offers a line of anti-aging products that includes day cream, night cream, hand and body lotion, and sunscreen. Skinvisible’s foray into Greater China is in line with its strategy of driving Kintari-branded product sales through subsidiaries in the U.S. and Canada and international distribution and licensing agreements.

Along with Skinvisible’s cosmeceutical and over-the-counter products, Skinvisible has signed a letter of intent with Quoin Pharmaceuticals Inc. to merge the two companies and to pursue additional medical conditions, such as post-surgical pain and PTSD with suicidal thoughts in the military.

For more information, visit the company’s website at www.Skinvisible.com

Proposed Merger Expands SKVI Horizons into Multi-Billion Dollar Pain Market

- Company has developed and licensed novel drug delivery systems and products for over 15 years
- With 14 patents, Skinvisible has proven efficacy and global reach
- Proposed merger may transform non-opioid pain market

At the cutting edge of innovative drug delivery technology since 1999, Skinvisible, Inc. (OTCQB: SKVI), in a recently announced Letter of Intent of a proposed merger with Quoin Pharmaceuticals, is now expanding its horizons into the global pain management therapeutics market. The pain management therapeutics market is projected to expand at a 3.7 percent CAGR and exceed $83 billion in the United States by 2024 (http://nnw.fm/2GytJ). Skinvisible, through wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology. The proposed merger with Quoin Pharmaceuticals (http://nnw.fm/L6Fjc) would combine Skinvisible’s patented and proven novel drug delivery technologies that enhance the delivery of various active ingredients with Quion’s strong pharmaceutical background in post-surgical pain and promising approach to PTSD treatment.

Skinvisible has a long, successful history developing and licensing Invisicare®, its patented polymer technology. Enhancing how drugs are delivered on, in, or through the skin, Invisicare® has proven efficacy in a wide range of dermatology and health care products, including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis. Broad applications extend to sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations and, now, with a Quoin merger, the enhanced delivery of important non-opioid pain management medications.

With a focus on a lucrative licensing model and over 40 products developed in topical dermatology, Skinvisible has already achieved impressive market traction. The company offers a premium line of scientifically formulated, highly effective skincare products powered by its Invisicare® technology and has revolutionized the topical sunscreen market with Skinbrella®, a patented broad-spectrum 80-minute water-resistant sunscreen that meets or exceeds all FDA requirements.

Last year, Skinvisible completed its first international sale of alcohol-free DermSafe® hand sanitizers in China. DermSafe® utilizes a unique formulation that provides a long-lasting protective barrier that binds to the skin for hours and reduces the spread of germs between people and hard surfaces. In September 2017, the company signed a breakthrough exclusive license agreement with Canopy Growth (TSX: WEED) for two distinct cannabis- and hemp-based topical product lines aimed at enhancing penetration of topically used cannabis products.

With 14 patents granted surrounding its novel drug delivery systems and products, it’s little wonder that Quoin Pharmaceuticals looks to merge with Skinvisible. Delivering enhanced and effective non-opioid pain relief is the current Holy Grail of pharmacology, and Skinvisible’s contribution to what may become transformative pain management delivery shouldn’t be underestimated.

For more information, visit the company’s website at www.Skinvisible.com

SKVI and Quoin Pharmaceuticals to Provide Opioid-free Pain Relief Solution

Topical and transdermal product development company Skinvisible (OTCQB: SKVI), through its recently entered non-binding merger agreement with Quoin Pharmaceuticals Limited, is planning to create a solution to the opioid crisis that is currently plaguing America. An article discussing this reads: “In response to the substance abuse epidemic sweeping the nation, Congress passed the 21st Century Cures Act, which was signed into law by President Obama in December 2016. The legislation allocates over $1 billion to a variety of programs, some of which will attempt to wean patients away from addictive opium derivatives, a push unlikely to cause any degradation in pain management regimens. Non-opiates, in many instances, have proven to be just as effective for pain relief as oxycodone, hydrocodone or codeine, some widely used opioids. In October 2017, President Trump declared a public health emergency to deal with the opioid epidemic. Now that opioid use has reached crisis levels, bringing benign alternatives to market could rescue thousands from the perils of addiction. Skinvisible, Inc. (OTCQB: SKVI) plans to do exactly that. It is teaming up with Quoin Pharmaceuticals, in a proposed merger, to provide pain management products that, unlike opioids, do not provide a cure that is worse than the disease.”

To view the full article, visit http://nnw.fm/IGbj4

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com.

SKVI Proposed Merger with Quoin to Provide 21st Century Cures

- Substance use disorder (SUD) has reached crisis proportions
- Deal links Quoin’s non-opioid analgesics to Skinvisible’s drug delivery system
- Market for opioids is currently about $6 billion annually

Opioids are killing Americans at an alarming rate. Every day ‘91 Americans die… from an opioid overdose’, according to the Centers for Disease Control and Prevention (CDC). In response to the substance abuse epidemic sweeping the nation, Congress passed the 21st Century Cures Act, which was signed into law by President Obama in December 2016. The legislation allocates over $1 billion to a variety of programs, some of which will attempt to wean patients away from addictive opium derivatives, a push unlikely to cause any degradation in pain management regimens. Non-opiates, in many instances, have proven to be just as effective for pain relief as oxycodone, hydrocodone or codeine, some widely used opioids. In October 2017, President Trump declared a public health emergency to deal with the opioid epidemic. Now that opioid use has reached crisis levels, bringing benign alternatives to market could rescue thousands from the perils of addiction. Skinvisible, Inc. (OTCQB: SKVI) plans to do exactly that. It is teaming up with Quoin Pharmaceuticals, in a proposed merger, to provide pain management products that, unlike opioids, do not provide a cure that is worse than the disease.

The abuse of opioids and other substances continues globally to be a vexing public health issue. The number of people reporting a substance use disorder (SUD) is on the rise, a development attributed to illicit opioids like heroin and opium but also, more alarmingly, to prescription opioid pain relievers (OPRs). The effects have been devastating. In 2015, 33,091 Americans died due to an accidental or unintentional opioid-related overdose. OPR abuse is largely responsible for the increase in SUD fatalities. ‘Deaths from prescription opioids—drugs like oxycodone, hydrocodone, and methadone—have more than quadrupled since 1999’, according to one CDC study (http://nnw.fm/Si7EU). This fourfold increase is in line with the volume of OPRs dispensed: ‘The amount of prescription opioids sold to pharmacies, hospitals, and doctors’ offices nearly quadrupled from 1999 to 2010’, a development that has been blamed on system failure (http://nnw.fm/wUc3k). There is, obviously, a pressing need for less pernicious painkillers. Luckily, there are indications that some non-opiates can be just as effective at reducing pain, as a recent study shows (http://nnw.fm/tbN2A).

Announcing the proposed merger with Quoin Pharmaceuticals Limited, Skinvisible provided an update on how it proposes to address this crisis (http://nnw.fm/Q4cye). The proposed first lead product, QRX001, is a single use transdermal non-competitive NMDA receptor antagonist intended for the treatment of post-surgical pain. An NMDA receptor antagonist is a type of anesthetic that inhibits the action of the N-Methyl-D-aspartate receptor (NMDAR). Transdermal medicines are those applied to the surface of the skin that then penetrate into the blood stream. QRX001 is expected to provide up to 72 hours of effective analgesia post-surgically, eschewing the use of any opioid.

About half of those addicted were first introduced to opioids to combat pain after surgery. QRX001, when developed, may provide surgeons with a more effective alternative to opioids and to current opioid sparing products such as intravenous NSAIDs. The current market for opioids in the U.S. is estimated at $6 billion annually, and the highly differentiated nature of QRX001 could position it to capture significant market share either as a monotherapy or as part of multi-modal therapy. An application for Fast Track status for QRX001 will be filed.

The proposed merger with Quoin will allow Skinvisible to enter the post-surgical pain management market. The post-merger entity is expected to carry the name Quoin Pharmaceuticals Inc. and be listed on the OTCQB Venture Market.

For more information, visit the company’s website at www.Skinvisible.com

SKVI Could Create Non-opioid Pain Solution for Rising Population of Senior Citizens

Skinvisible (OTCQB: SKVI), a topical and transdermal product development company, recently entered a non-binding merger with Quoin Pharmaceuticals Limited. The two companies are expected to deliver a non-opioid solution to pain sufferers. An article discussing this reads: “Health professionals are preparing for an expected doubling of the 65 years and older population within the next 30 years, creating medical need to address the pain that often becomes a prevalent companion to age. While modern pharmaceuticals have developed opioids and non-steroidal therapies for reducing chronic pain, the drugs are often accompanied by addiction and unwanted side effect concerns. However, Skinvisible, Inc.’s (OTCQB: SKVI) recently announced non-binding merger with Quoin Pharmaceuticals Limited is creating a partnership that may provide alternative solutions at a time when they are needed the most.”

To view the full article, visit http://nnw.fm/DtDr5

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com or www.Invisicare.com.

SKVI Partnership with Quoin Focuses on Population’s Pain Needs

- Non-binding proposed merger announced on November 27, 2017
- Quoin merger expected to deliver non-opioid relief to post-surgical patients
- Over-65 population with advanced pain needs expected to double within next 30 years
- Skinvisible and Quoin proposed merger expected to deliver better results to patients

Health professionals are preparing for an expected doubling of the 65 years and older population within the next 30 years, creating medical need to address the pain that often becomes a prevalent companion to age. While modern pharmaceuticals have developed opioids and non-steroidal therapies for reducing chronic pain, the drugs are often accompanied by addiction and unwanted side effect concerns. However, Skinvisible, Inc.’s (OTCQB: SKVI) recently announced non-binding merger with Quoin Pharmaceuticals Limited is creating a partnership that may provide alternative solutions at a time when they are needed the most.

Quoin’s products include QRX001, which will provide 72 hours of effective non-opioid pain relief to post-surgical patients, and QRX002, which is an anticipated once-a-day solution for military PTSD patients at risk for suicidal tendencies. QRX001 will be formulated with an NMDA receptor antagonist that has undergone almost 30 pre-clinical trial studies in the United States. The studies have shown that sub-anesthetic doses of the compound reduced morphine consumption controlled by the patient, as well as post-operative nausea and the reported intensity of pain, while adverse events were reportedly mild or non-existent. QRX001 is anticipated to undergo a phase II trial in the coming year.

Leveraging these results, Skinvisible and Quoin hope to help reduce the abuse of prescription painkillers, which has received classification as a national health emergency (http://nnw.fm/5Nh0T). In a recent study reported in JAMA Surgery, 36,000 post-operative patients’ painkiller use was tracked over the course of a half year. The study found that five to six percent of the patients “continued to fill prescriptions for opioids long after what would be considered normal surgical recovery” (http://nnw.fm/K84Dc). In 2016, drug overdose deaths, the majority of them blamed on painkiller dependency, reportedly rose nearly 20 percent over those reported in 2015, according to the New York Times (http://nnw.fm/27Inj). The Centers for Disease Control and Prevention reported that opioid-related deaths quadrupled between 1999 and 2015 on par with a commensurate increase in the sale of prescription opioids to pharmacies and medical offices during that period (http://nnw.fm/V60zK).

“Pain is prevalent and often under-treated among older adults,” University of Texas at Arlington researcher Robert Gatchel said in a December statement to MD Magazine (http://nnw.fm/iUk9p). “With 20 percent of Americans expected to be 65 or older by 2030, the development of new and effective pain management strategies is a necessity, especially given that 75 percent of people in this age group have two or more chronic conditions such as heart disease, arthritis or diabetes, which complicate the taking of pain medications.”

The completion of the merger between Skinvisible and Quoin is subject to the negotiation of a definitive agreement and other customary closing conditions, including Quoin completing a financing round for clinical development.

For more information, visit the company’s website at www.Skinvisible.com

Russia reports outbreak of highly pathogenic H5N2 bird flu: OIE

DECEMBER 29, 2017 / 8:29 AM / UPDATED 2 HOURS AGO

Reuters Staff
1 MIN READ
PARIS (Reuters) - Russia has reported an outbreak of highly pathogenic H5N2 bird flu on a farm in the Kostromskaya Oblast region, the Paris-based World Organisation for Animal Health (OIE) said on Friday.

The disease was detected on Dec. 17 and led to the culling of more than 660,000 birds, the OIE said, citing a report from the Russian ministry of agriculture.

It did not specify the type of birds that were infected.

SKVI Prepares to Address Killer Drug Epidemic Through Proposed Merger Agreement

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) recently signed a letter of intent regarding a proposed merger with Quoin Pharmaceuticals Limited. The two companies intend to work together to address the opioid epidemic plaguing America. An article discussing this reads: “There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed merger, with expected completion in early 2018, that will result in a new entity, Quoin Pharmaceuticals Inc. Upon completion of this merger, the new company (combining Quoin’s strengths of pharmaceutical development and Skinvisible’s innovative technologies that enhance delivery and product performance) has tremendous potential to address the significant needs of the pain management market.”

To view the full article, visit http://nnw.fm/Xj8MK

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com or www.Invisicare.com.

SKVI and Quoin Poised to Tackle Opioid Crisis with Alternative Pain Therapies

- A possible larger role for leading drug manufacturers, and the resulting opioid epidemic, is met with increased public and government demands for alternative therapies
- The Skinvisible and Quoin merger, with expected completion in 2018, will create an enterprise positioned to disrupt the $6 billion U.S. opioid market by producing and delivering non-opioid alternatives for pain management
- Quoin’s QRX001 is slated to provide alternative and effective pain management in the post-surgical setting, where 50 percent of opioid addictions start

A recent article by the Washington Post (http://nnw.fm/ikb1U) addressed the opioid crisis, suggesting a larger role by leading pharmaceutical drug manufacturers than originally thought. The story alludes to the possibility that “drug manufacturers and distributors turned a willfully blind eye toward illegal drug trafficking.” In the midst of this, there is an opioid epidemic that has been deemed a national health emergency that results in 90 deaths per day (http://nnw.fm/V60zK) and is growing exponentially, according to the Centers for Disease Control and Prevention.

There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed merger, with expected completion in early 2018, that will result in a new entity, Quoin Pharmaceuticals Inc. Upon completion of this merger, the new company (combining Quoin’s strengths of pharmaceutical development and Skinvisible’s innovative technologies that enhance delivery and product performance) has tremendous potential to address the significant needs of the pain management market.

One of the main areas of Quoin’s focus is to disrupt the opioid market (currently estimated at $6 billion annually in the U.S. alone) and produce and deliver to market non-opioid products that serve as effective and viable alternatives for the immense pain management market. This focus will include all areas of pain management, including critical needs in the post-surgical setting. At least 50 million U.S. surgeries require the use of post-operative pain management pharmaceuticals annually, and it is in the post-surgical setting that about 50 percent of opioid addictions begin.

To address the critical demands for effective alternatives to opioids, Quoin will launch one of its first lead products, QRX001, for effective treatment of post-surgical pain. The product, a transdermal NMDA receptor antagonist, delivers up to 72 hours of effective post-surgical pain relief. With the aim of providing alternatives to opioids as well as opiates, numerous clinical studies on QRX001 have shown that sub-anesthetic doses have resulted in a marked 24-hour reduction in PCA morphine consumption. In addition, clinical tests of the NMDA receptor antagonist generated superior results to any single existing product or combination and resulted in mild or absent adverse events, reduced post-surgical nausea and vomiting and reduced pain intensity.

With completion of the merger of Skinvisible and Quoin expected in early 2018, the synergies of the merged technologies, expertise and proven track records poise the new Quoin Pharmaceuticals with tremendous potential to address the needs of the immense pain market and tackle the opioid epidemic head-on.

For more information, visit the company’s website at www.Skinvisible.com

SKVI May Target Booming Pain Management Market Through Proposed Merger with Quoin Pharmaceuticals

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) recently signed a Letter of Intent (“LOI”) regarding a proposed merger with Quoin Pharmaceuticals Limited. The potential partnership could target significant unmet medical needs on the pain management market. An article discussing this reads: “Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even larger. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.”

To view the full article, visit http://nnw.fm/tI2kk

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com or www.Invisicare.com.

If you would like to know the current O/S you can contact this man.



As of today Skinvisible O/S 136,864,035, no change in authorized

Best Regards
Brian Barthlow
Empire Stock Transfer Inc.
1859 Whitney Mesa Dr.
Henderson, Nevada 89014
brian@empirestock.com | P (702) 818-5898 | F (702) 974-1444 | www.empirestock.com

We are a full-service agent offering:
Transfer Agent & Registrar | EDGAR Filings | Proxy/Annual Meetings | Resident Agent Services

Let us do what we do best so you can do what you do best – run your business.
Small Cap Agents for Today’s Business

Maybe the Dilution has stoped? we won't have another run until they are finished converting




Outstanding Shares 132,839,035 a/o Nov 09, 2017

Outstanding Shares 136,864,035 a/0 Dec 16 2017

4,025,000 Shares diluted since NOV 9,2017

Up to 255,000 shares now.... Loving the dip

Proposed SKVI, Quoin Pharmaceuticals Merger to Address Opioid Pain Management Market

- A merger between Skinvisible and Quoin Pharmaceuticals will enable a successful entry on the post-surgical pain management market
- Aging populations and a large number of surgical interventions in the West have contributed to significant market expansion
- By 2024, the pain management therapeutics market is expected to reach $83 billion

Skinvisible Pharmaceuticals (OTCQB: SKVI) recently announced that it has signed a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market. If both parties agree on the terms, the merger should be completed next year, with the resulting entity operating under the name Quoin Pharmaceuticals Inc. and continuing to trade on the OTCQB Venture Market.

Quoin’s strength is within the area of pharmaceutical development for products that address some of the most serious present-day health problems. Skinvisible is the developer of innovative delivery system technologies that can enhance product performance.

One of Quoin’s first lead products is QRX001 – a transdermal NMDA receptor antagonist for the effective treatment of pain following surgery. QRX001 delivers up to 72 hours of effective pain relief following surgical interventions. Almost 30 clinical studies have been performed to date on the NMDA receptor antagonist, clearly showing that sub-anesthetic doses reduced 24-hour PCA morphine consumption, reduced post-operative nausea and vomiting, reduced pain intensity and resulted in adverse events that were mild or absent, all while generating better results than any other existing single product or combination. The aim of the product is to also reduce the use of opioids for pain management following operations.

The opioid market in the US is estimated at $6 billion annually. With the opioid epidemic now deemed a National Health Emergency, there is a significant push to find new products that reduce or eliminate their use, particularly in a post-surgical setting, which is where 50 percent of people who become addicted first become exposed to these drugs.

Upon the product’s launch, QRX001 will provide surgeons with a new and effective alternative to opioids. Opioid abuse has reached an epidemic level in the U.S., with opioid overdoses causing more than 90 deaths per day (http://nnw.fm/V60zK). The number has grown exponentially in the past decade, according to the Centers for Disease Control and Prevention, with opioid use remaining widespread despite the risks.

Today, approximately 12 million Americans report that they use pain killers in a non-medicinal way. Almost half of these victims were first introduced to opioids after undergoing surgery. According to the National Center for Health Statistics, 100 million surgeries take place in the U.S. every year (http://nnw.fm/8fdOl). At least 50 million of these surgical interventions necessitate the use of post-operative pain management pharmaceuticals.

Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even larger. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.

A proposed second product that could hit the market sooner as a result of the proposed merger is QRX002 – a transdermal NMDA receptor antagonist for the treatment of suicidal tendencies in military veterans suffering from PTSD. The product will be intended for use once per day. The fight against PTSD is of profound importance, as estimates suggest that anywhere between 25 and 30 veterans commit suicide in the U.S. every day.

A Skinvisible announcement states that new technologies and product synergies between the two companies could potentially provide significant value to shareholders following the proposed merger. Together, Skinvisible and Quoin could maximize their product development opportunities, as noted by Skinvisible President Terry Howlett in a recent news release (http://nnw.fm/f2coB).

For more information, visit the company’s website www.Skinvisible.com

SKVI Advances Invisicare Delivery System

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) is targeting the pharmaceutical industry with its proprietary drug delivery system, Invisicare. Invisicare improves the delivery of ingredients to and through the skin. An article discussing this reads: “Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries. The company’s business model emphasizes four revenue streams that include fees for new product development, license fees, sales of branded products, and on-going royalty fees based on a licensee’s sales.”

To view the full article, visit http://nnw.fm/IlUp7

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com or www.Invisicare.com.

it likely not retail selling...more like establishment swapping and stealing shares from the discouraged and impatients...

New Exclusive Licensing Agreement with Cannabiniers, Conducted via Lighthouse Strategies with SKVI Subsidiary

- Cannabis industry pioneer Cannabiniers will distribute treatments utilizing Invisicare®, a patented polymer delivery system
- Agreement marks continued growth for Skinvisible’s subsidiary Ovation Science Inc.
- Patented delivery technology enables improved controlled release of topically applied products

Research and development company Skinvisible, Inc. (OTCQB: SKVI) has announced that its subsidiary Ovation Science Inc. has forged a definitive license agreement with Lighthouse Strategies LLC, through its multifaceted cannabis technology and brand management company Cannabiniers, to utilize the Company’s products formulated with its patented pharmaceutical polymer in serving the U.S. cannabis market (http://nnw.fm/3kZGm).

The Lighthouse agreement grants the company exclusive use of Ovation’s new patented topical and transdermal formulations for improved delivery of ingredients in select markets within the United States. This latest agreement is yet another mark of Ovation’s expansion, which has included another recently signed licensing agreement granting Canopy Growth Corp. exclusive rights to Ovation’s cannabis formulations in Canada (http://nnw.fm/l60IQ).

As part of the agreement via Lighthouse, and in cooperation with the Advocacy Research Center, Cannabiniers will distribute cannabis-based treatments utilizing Ovation’s patented technology through its national manufacturing and distribution channels. In distributing these treatments throughout the U.S., Cannabiniers will help foster the development of healthy, safe, lifestyle-centered topical and transdermal cannabis treatments that feature the added asset of accurate time-released dosing.

Cannabiniers’ goal is to standardize cannabis use and foster its integration into the daily lives of patients and consumers—something the company has achieved with its own current brands and now intends to do with Ovation’s topical products, which feature a patented and game-changing delivery technology.

These products will initially be released through Silver State Wellness and San Diego ReLeaf, which are licensed marijuana cultivators and manufacturers of infused products servicing Nevada and California. Ovation’s technology will enable these entities to offer unique topical and transdermal cannabis products that let individuals treat themselves in a comfortable and reliable way while maintaining their everyday lifestyles.

Skinvisible is an R&D company engaged in licensing its proprietary formulations made with Invisicare®, which is the company’s patented polymer delivery system that offers life-cycle management and distinctive enhancements for topically delivered products. Invisicare uniquely allows controlled release of active ingredients and the ability to hold these ingredients on the skin for extended time periods.

Ovation Science is a Canadian subsidiary of Skinvisible holding all the rights to the Company’s cannabis formulations.

For more information, visit the company’s websites at www.Skinvisible.com or www.Invisicare.com

SKVI buy 0.0568

bull flag

















normal chart




log chart

I decided to sell out of this, managment is incompetent, Good luck. May have dropped due to me closing my position.

Up your Asks over .06 .07 your just beating the stock down selling at .05

Anybody still watching this board other than NetworkNewswire? They sure like to spam this board lol

SKVI Poised for Growth More than Skin Deep

Skinvisible (OTCQB: SKVI) is poised for growth in the booming global topical drug delivery market. A recent article highlights the company’s positioning, stating, “The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow at a CAGR of 9.2% from USD 101.7 billion in 2016 to reach USD 205.1 billion by 2024. This is good news for Skinvisible, which derives part of its revenues from royalties and other product licensing fees. The Company is already having success in this area. It has announced a number of licensing agreements. As the global topical market continues its robust growth, Skinvisible’s licensing business appears more than skin deep.”

To view the full article, visit http://nnw.fm/Qm2P8

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com or www.Invisicare.com.